Pharmacotherapeutic Management of Pulmonary Arterial Hypertension

被引：55

作者：

Anderson, Joe R. ^{[1
]}

Nawarskas, James J. ^{[1
]}

机构：

[1] Univ New Mexico, Coll Pharm, Albuquerque, NM 87131 USA

来源：

CARDIOLOGY IN REVIEW | 2010年 / 18卷 / 03期

关键词：

pulmonary arterial hypertension; phosphodiesterase type 5 inhibitors; endothelin receptor antagonists; prostacyclin; prostacyclin analogues; ENDOTHELIN-RECEPTOR ANTAGONIST; CONTINUOUS INTRAVENOUS EPOPROSTENOL; ACTIVE PROSTACYCLIN ANALOG; CALCIUM-CHANNEL BLOCKERS; QUALITY-OF-LIFE; DOUBLE-BLIND; INHALED ILOPROST; NITRIC-OXIDE; AMBRISENTAN THERAPY; COMBINATION THERAPY;

D O I：

10.1097/CRD.0b013e3181d4e921

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Pulmonary arterial hypertension (PAH) is a disabling chronic disorder of the pulmonary vasculature, which is characterized by increased pulmonary artery pressure as a result of increased pulmonary vascular resistance. The pathology of PAH is characterized by pulmonary vascular vasoconstriction, smooth muscle cell proliferation, and thrombosis. These changes are a result of an imbalance between vasodilators (prostacyclin, nitric oxide, vasoactive intestinal peptide) and vasoconstrictors (thromboxane A2, endothelin, serotonin), growth inhibitors and mitogenic factors, and antithrombotic and prothrombotic factors. Recent advances in treatment are directed at restoring the balance between these systems. Endothelin receptor antagonists (bosentan, ambrisentan, sitaxsentan), phosphodiesterase type 5 inhibitors (sildenafil, tadalafil), and prostacylin (epoprostenol, iloprost, treprostinil, beraprost) represent the different classes of medications that are currently used in monotherapy and in combination to treat PAH. The purpose of this drug highlight is to provide the reader with an update of the pharmacotherapeutic treatment of PAH.

引用

页码：148 / 162

页数：15

共 122 条

[1] Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension [J].

Aizawa, K ;

Hanaoka, T ;

Kasai, H ;

Kogashi, K ;

Kumazaki, S ;

Koyama, J ;

Tsutsui, H ;

Yazaki, Y ;

Watanabe, N ;

Kinoshita, O ;

Ikeda, U .

HYPERTENSION RESEARCH, 2006, 29 (02) :123-128

[2]

[Anonymous], 2008, Information for Healthcare Professionals: Micro-bubble Contrast Agents (marketed as Definity (Perflutren Lipid Microsphere) Injectable Suspension and Optison (Perflutren Protein-Type A Microspheres for Injection)

[3]

[Anonymous], 2009, TRACL PRESCR INF

[4]

[Anonymous], EFFECTS COMBINATION

[5] NITRIC-OXIDE AND CGMP CAUSE VASORELAXATION BY ACTIVATION OF A CHARYBDOTOXIN-SENSITIVE K-CHANNEL BY CGMP-DEPENDENT PROTEIN-KINASE [J].

ARCHER, SL ;

HUANG, JMC ;

HAMPL, V ;

NELSON, DP ;

SHULTZ, PJ ;

WEIR, EK .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (16) :7583-7587

[6]

Badesch DB, 2009, AM J RESP CRIT CARE, V179

[7] Medical therapy for pulmonary arterial hypertension - Updated ACCP evidence-based clinical practice guidelines [J].

Badesch, David B. ;

Abman, Steven H. ;

Simonneau, Gerald ;

Rubin, Lewis J. ;

McLaughlin, Vallerie V. .

CHEST, 2007, 131 (06) :1917-1928

[8] Diagnosis and Assessment of Pulmonary Arterial Hypertension [J].

Badesch, David B. ;

Champion, Hunter C. ;

Gomez Sanchez, Miguel Angel ;

Hoeper, Marius M. ;

Loyd, James E. ;

Manes, Alessandra ;

McGoon, Michael ;

Naeije, Robert ;

Olschewski, Horst ;

Oudiz, Ronald J. ;

Torbicki, Adam .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (01) :S55-S66

[9] Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].

Badesch, DB ;

Tapson, VF ;

McGoon, MD ;

Brundage, BH ;

Rubin, LJ ;

Wigley, FM ;

Rich, S ;

Barst, RJ ;

Barrett, PS ;

Kral, KM ;

Jöbsis, MM ;

Loyd, JE ;

Murali, S ;

Frost, A ;

Girgis, R ;

Bourge, RC ;

Ralph, DD ;

Elliott, CG ;

Hill, NS ;

Langleben, D ;

Schilz, RJ ;

McLaughlin, VV ;

Robbins, IM ;

Groves, BM ;

Shapiro, S ;

Medsger, TA ;

Gaine, SP ;

Horn, E ;

Decker, JC ;

Knobil, K .

ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+

[10] Medical therapy for pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines [J].

Badesch, DB ;

Abman, SH ;

Ahearn, GS ;

Barst, RJ ;

McCrory, DC ;

Simonneau, G ;

McLaughlin, VV .

CHEST, 2004, 126 (01) :35S-62S

← 1 2 3 4 5 6 7 8 9 10 →